Have you ever conducted a study on the development or testing of a measurement instrument applicable to patients with a shoulder condition?
Yes, (if so, please specify the number of studies ___) No
Have you ever participated in the development of a core outcome measurement set for any health condition?
Yes (if so, please specify the number of core outcome sets ___) No 
Domain questions

Question
Response option in a core domain set for clinical trials of shoulder conditions? In some clinical trials, tests are used for diagnostic purposes to decide if the person is eligible for the trial (e.g. 'painful arc test' or 'Neer impingement test' or 'empty can test' for rotator cuff disease; 'apprehension test' or 'relocation test' for shoulder instability). In some trials, these examinations are repeated post-treatment to assess whether or not the test is still positive, which suggests that the shoulder condition is still present. An example of an examination is presented here: http://www.physiopedia.com/Painful_Arc Unsure/I do not know Please provide any comments you wish to justify your response to the above question Is the domain 'Shoulder Instability' important enough to be included in a core domain set for clinical trials of shoulder conditions? 'Shoulder Instability' is defined here as: 'loosening of connective tissue surrounding the shoulder joint which enables the bones forming the joint to move excessively on each other. In some cases the upper arm bone (humerus) may move partially or completely out of the socket during certain arm movements (i. Ideally, how many domains would you include in this core domain set for clinical trials of shoulder conditions? Please try to answer this question regardless of your rating during this survey.
Number: ___ (please specify why)
The presence (or not) of adverse events should always be reported in all clinical trials. Following OMERACT guidance, a recommendation for the reporting of adverse events should be included in every core outcome set. For this core outcome set, we propose an approach that demands a conceptual separation between adverse events and core domains. This means that a measured adverse event would only be defined as an adverse event if belongs to a different domain than one of the core domains. The following hypothetical example is provided for illustrative purposes. Suppose that this core domain set has already been defined and "Pain Intensity", "Physical Functioning" and "Work Productivity" are the core domains included. In this case a patient with an increase in pain intensity due to treatment cannot be defined as an adverse event because it belongs to one of the core domains (i.e. Pain Intensity). In fact, this increase in pain intensity would be summarized within the group results
Yes
No (please specify why) Not my expertise
Question
Response option for that domain. However, people who report symptoms such as dizziness or nausea (or any other bad event or outcome following treatment would be defined as adverse events. Do you agree with this approach to defining adverse events? Different aspects should be taken into account when reporting the presence of adverse events. Examples of these aspects are: distinction between serious and nonserious adverse events, adverse events that can be intervention-specific, adverse events that can be treatment-related or not. Do you have any suggestion on how adverse events should be reported in shoulder condition clinical trials? [Free text] 
